NEW YORK (GenomeWeb News) – Transgenomic today announced an agreement to provide genetic testing services for Raptor Pharmaceuticals' clinical trial evaluating its drug called RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.